Previous 10 |
The first patient has been dosed in a Phase 1 dose-escalation study evaluating Pieris Pharmaceuticals' ( PIRS +2.9% ) PRS-343, combined with Roche's Tecentriq (atezolizumab), in patients with advanced/metastatic HER2-positive solid tumors. More news on: Pieris Pharmaceuticals, Inc., ...
BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer, respiratory and other diseases, announced today that...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
2024-07-27 03:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...